SBIR Phase I: Covert Combinatorial DNA Taggants Signatures for Authentication, Tracking and Trace-Back

SBIR 第一阶段：用于身份验证、跟踪和追溯的隐蔽组合 DNA 标签签名

• 批准号: 0944491
• 负责人: Anthony Macula
• 金额: --
• 依托单位: Anthony J. Macula
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-01-01 至 2010-12-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=0944491&HistoricalAwards=false
• 关键词: SBIR; Phase; Covert; Combinatorial; DNA

This Small Business Innovation Research (SBIR) Phase I project develops a new biomolecular covert taggant method that marks objects with synthetic DNA nano-scale biosensors, called ComDTags, for verification of authenticity and for forensic track and trace-back. Pharmaceutical companies, brand owners and governments need thousands of covert and unique signatures to protect their drugs, products, documents and citizens. Using DNA for this purpose is environmentally safe, but to date, no DNA taggant method can produce enough unique and information-rich signatures. This project expects to demonstrate that the ComDTag DNA taggant system can easily construct millions of unique, information-rich and covert DNA signatures and that these signatures can be detected and decoded only by authorized users. The broader impacts of this research are anti-counterfeiting, authentication and quality control technologies. Counterfeiting costs the U.S. economy $200 billion per year and is responsible for the loss of 750,000 American jobs. The counterfeiting of the drug heparin has been linked to the deaths of over a hundred Americans with hundreds more having severe allergic reactions. These disturbing facts indicate that there is an increasing need for safe and covert methods to prevent, track and trace-back counterfeit products. Covert ComDTag signatures can feasibly meet these needs. Combined with more overt taggant products, ComDTag signatures can yield more robust, secure and useful covert track and trace-back solutions for commercial and national security interests.

这个小企业创新研究（SBIR）第一阶段项目开发了一种新的生物分子隐蔽标记方法，该方法使用合成DNA纳米级生物传感器（称为ComDTags）标记物体，用于验证真实性以及法医跟踪和追溯。 制药公司、品牌所有者和政府需要数千个隐蔽和独特的签名来保护他们的药物、产品、文件和公民。 为此目的使用DNA是环境安全的，但迄今为止，没有DNA标签剂方法可以产生足够独特和信息丰富的签名。该项目旨在证明ComDTag DNA标记物系统可以轻松构建数百万个独特的、信息丰富的和隐蔽的DNA签名，并且这些签名只能由授权用户检测和解码。这项研究的更广泛影响是防伪，认证和质量控制技术。伪造货币每年给美国经济造成2000亿美元的损失，并导致75万美国人失业。假冒肝素药物与100多名美国人的死亡有关，其中数百人有严重的过敏反应。这些令人不安的事实表明，越来越需要安全和隐蔽的方法来防止，跟踪和追溯假冒产品。隐蔽ComDTag签名可以切实满足这些需求。与更公开的标签产品相结合，ComDTag签名可以为商业和国家安全利益提供更强大，安全和有用的隐蔽跟踪和追溯解决方案。